Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide

Journal of the Royal Society Interface

Volumn 13, Issue 122, 2016, Pages

  Pretorius, Etheresia ^a   Mbotwe, Sthembile ^a   Bester, Janette ^a   Robinson, Christopher J ^b   Kell, Douglas B ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Amyloid; Bacterial lipopolysaccharide; Electron microscopy; Fibrin; Plasma; Thromboelastography

Indexed keywords

AMPLIFICATION; BLOOD; COAGULATION; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; GLYCOPROTEINS; PLASMAS; VISCOELASTICITY;

AMYLOID; FIBRIN; INFLAMMATORY CONDITIONS; ISOTHERMAL CALORIMETRY; LIPOPOLYSACCHARIDES; MOLECULAR AMPLIFICATION; THROMBOELASTOGRAPHY; VISCOELASTIC PROPERTIES;

DISEASES;

AMYLOID BETA PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; FIBRIN; FIBRINOGEN; THROMBIN; AMYLOID; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI O111 B4;

ADULT; AMYLOIDOGENIC BLOOD CLOTTING; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRIN POLYMERIZATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN EXPERIMENT; HYPERCOAGULABILITY; IN VIVO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MALE; NORMAL HUMAN; STOICHIOMETRY; THROMBOCYTE POOR PLASMA; THROMBOELASTOGRAPHY; VISCOELASTICITY; DRUG EFFECTS; METABOLISM;

AMYLOID; BLOOD COAGULATION; FEMALE; FIBRIN; FIBRINOGEN; HUMANS; LIPOPOLYSACCHARIDES; MALE; THROMBELASTOGRAPHY; THROMBIN;

EID: 84988820225     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2016.0539     Document Type: Article

References (72)

1. Jiang W et al. 2009 Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199, 1177-1185. (doi:10.1086/597476)
2. Harte AL et al. 2010 Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. (Lond.) 7, 15. (doi:10.1186/1476-9255-7-15)
3. Su W, Ding X. 2015 Methods of endotoxin detection. J. Lab. Autom. 20, 354-364. (doi:10.1177/2211068215572136)
4. Novitsky TJ. 1998 Limitations of the Limulus amebocyte lysate test in demonstrating circulating lipopolysaccharides. Ann. N. Y. Acad. Sci. 851, 416-421. (doi:10.1111/j.1749-6632.1998.tb09018.x)
5. Kell DB, Pretorius E. 2015 On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr. Biol. 7, 1339-1377. (doi:10.1039/C5IB00158G)
6. Potgieter M, Bester J, Kell DB, Pretorius E. 2015 The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol. Rev. 39, 567-591. (doi:10.1093/femsre/fuv013)
7. Kell DB, Potgieter M, Pretorius E. 2015 Individuality, phenotypic differentiation, dormancy and 'persistence' in culturable bacterial systems: commonalities in environmental, laboratory, and clinical microbiology. F1000Research 4, 179.
8. De Punder K, Pruimboom L. 2015 Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front. Immunol. 6, 223. (doi:10.3389/fimmu.2015.00223)
9. Tan Y, Kagan JC. 2014 A cross-disciplinary perspective on the innate immune responses to bacterial lipopolysaccharide. Mol. Cell 54, 212-223. (doi:10.1016/j.molcel.2014.03.012)
10. Płóciennikowska A, Hromada-Judycka A, Borzȩcka K, Kwiatkowska K. 2015 Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell. Mol. Life Sci. 72, 557-581. (doi:10.1007/s00018-014-1762-5)
11. Rutherford NJ, Sacino AN, Brooks M, Ceballos-Diaz C, Ladd TB, Howard JK, Golde TE, Giasson BI. 2015 Studies of lipopolysaccharide effects on the induction of alpha-synuclein pathology by exogenous fibrils in transgenic mice. Mol. Neurodegener. 10, 32. (doi:10.1186/s13024-015- 0029-4)
12. Liu M, Bing G. 2011 Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis. 2011, 327089. (doi:10.4061/2011/327089)
13. Zielen S, Trischler J, Schubert R. 2015 Lipopolysaccharide challenge: immunological effects and safety in humans. Expert Rev. Clin. Immunol. 11, 409-418. (doi:10.1586/1744666X.2015. 1012158)
14. Frey D, Jung S, Brackmann F, Richter-Kraus M, Trollmann R. 2015 Hypoxia potentiates LPSmediated cytotoxicity of BV2 microglial cells in vitro by synergistic effects on glial cytokine and nitric oxide system. Neuropediatrics 46, 321-328. (doi:10.1055/s-0035-1562924)
15. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. 1999 Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J. Immunol. 162, 3749-3752.
16. Fujimoto Y, Shimoyama A, Suda Y, Fukase K. 2012 Synthesis and immunomodulatory activities of Helicobacter pylori lipophilic terminus of lipopolysaccharide including lipid A. Carbohydr. Res. 356, 37-43. (doi:10.1016/j.carres.2012. 03.013)
17. Medzhitov R. 2008 Origin and physiological roles of inflammation. Nature 454, 428-435. (doi:10.1038/nature07201)
18. Rossol M, Heine H, Meusch U, Quandt D, Klein C, Sweet MJ, Hauschildt S. 2011 LPS-induced cytokine production in human monocytes and macrophages. Crit. Rev. Immunol. 31, 379-446. (doi:10.1615/CritRevImmunol.v31.i5.20)
19. Savage CD, Lopez-Castejon G, Denes A, Brough D. 2012 NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front. Immunol. 3, 288. (doi:10.3389/fimmu.2012.00288)
20. Bryant CE, Spring DR, Gangloff M, Gay NJ. 2010 The molecular basis of the host response to lipopolysaccharide. Nat. Rev. Microbiol. 8, 8-14.
21. Croker BA, O'Donnell JA, Gerlic M. 2014 Pyroptotic death storms and cytopenia. Curr. Opin Immunol. 26, 128-137. (doi:10.1016/j.coi.2013.12.002)
22. Pedraza-Alva G, Pérez-Martínez L, Valdez-Hernández L, Meza-Sosa KF, Ando-Kuri M. 2015 Negative regulation of the inflammasome: keeping inflammation under control. Immunol. Rev. 265, 231-257. (doi:10.1111/imr.12294)
23. Choi G, Schultz MJ, Levi M, van der Poll T. 2006 The relationship between inflammation and the coagulation system. Swiss. Med. Wkly. 136, 139-144.
24. Conway EM. 2012 Thrombomodulin and its role in inflammation. Semin. Immunopathol. 34, 107-125. (doi:10.1007/s00281-011-0282-8)
25. Emsley HC, Tyrrell PJ. 2002 Inflammation and infection in clinical stroke. J. Cereb. Blood Flow Metab. 22, 1399-1419. (doi:10.1097/01.WCB. 0000037880.62590.28)
26. Esmon CT. 2005 The interactions between inflammation and coagulation. Br. J. Haematol. 131, 417-430. (doi:10.1111/j.1365-2141.2005. 05753.x)
27. Kell DB, Pretorius E. 2015 The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integr. Biol. 7, 24-52. (doi:10.1039/C4IB00173G)
28. Raskob GE et al. 2014 Thrombosis: a major contributor to global disease burden. Arterioscler. Thromb. Vasc. Biol. 34, 2363-2371. (doi:10.1161/ATVBAHA.114.304488)
29. Farrell DH. 2012 gamma' Fibrinogen as a novel marker of thrombotic disease. Clin. Chem. Lab. Med. 50, 1903-1909. (doi:10.1515/cclm-2012-0005)
30. Alexander KS, Madden TE, Farrell DH. 2011 Association between gamma' fibrinogen levels and inflammation. Thromb. Haemost. 105, 605-609. (doi:10.1160/TH10-09-0626)
31. Tonkin AM et al. 2015 Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: the LIPID biomarker study. Int. J. Cardiol. 201, 499-507. (doi:10.1016/j.ijcard.2015.07.080)
32. Halaby R et al. 2015 D-Dimer elevation and adverse outcomes. J. Thromb. Thrombolysis 39, 55-59. (doi:10.1007/s11239-014-1101-6)
33. Monroe DM, Key NS. 2007 The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J. Thromb. Haemost. 5, 1097-1105. (doi:10.1111/j.1538-7836.2007.02435.x)
34. Koch L, Hofer S, Weigand MA, Frommhold D, Poeschl J. 2009 Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography. Thromb. Res. 124, 463-467. (doi:10.1016/j.thromres.2009. 05.002)
35. Landsem A, Fure H, Christiansen D, Nielsen EW, Osterud B, Mollnes TE, Brekke OL. 2015 The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood. Clin. Exp. Immunol. 182, 81-89. (doi:10.1111/cei.12663)
36. Pretorius E, Mbotwe S, Bester J, Robinson C, Kell DB. In preparation. Acute induction of anomalous blood clotting by highly substoichiometric levels of bacterial lipopolysaccharide (LPS). (doi:10.1101/053538)
37. Lipinski B, Pretorius E. 2012 Novel pathway of ironinduced blood coagulation: implications for diabetes mellitus and its complications. Pol. Arch. Med. Wewn. 122, 115-122.
38. Pretorius E, Lipinski B, Bester J, Vermeulen N, Soma P. 2013 Albumin stabilizes fibrin fiber ultrastructure in low serum albumin type 2 diabetes. Ultrastruct. Pathol. 37, 254-257. (doi:10.3109/01913123.2013. 778929)
39. Pretorius E, Oberholzer HM, van der Spuy WJ, Swanepoel AC, Soma P. 2011 Qualitative scanning electron microscopy analysis of fibrin networks and platelet abnormalities in diabetes. Blood Coagul. Fibrinolysis 22, 463-467. (doi:10.1097/MBC. 0b013e3283468a0d)
40. Pretorius E, Bester J, Vermeulen N, Lipinski B. 2013 Oxidation inhibits iron-induced blood coagulation. Curr. Drug Targets 14, 13-19. (doi:10.2174/138945013804806541)
41. Pretorius E, Kell DB. 2014 Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr. Biol. 6, 486-510. (doi:10.1039/c4ib00025k)
42. Pretorius E, Steyn H, Engelbrecht M, Swanepoel AC, Oberholzer HM. 2011 Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients. Blood Coagul. Fibrinolysis 22, 696-700. (doi:10.1097/MBC.0b013e32834bdb32)
43. Landsem A, Nielsen EW, Fure H, Christiansen D, Ludviksen JK, Lambris JD, Osterud B, Mollnes TE, Brekke OL. 2013 C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. Clin. Exp. Immunol. 173, 217-229. (doi:10.1111/cei.12098)
44. Liu CC, Kanekiyo T, Xu H, Bu G. 2013 Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106-118. (doi:10.1038/nrneurol.2012.263)
45. Biancalana M, Koide S. 2010 Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim. Biophys. Acta 1804, 1405-1412. (doi:10.1016/j.bbapap.2010.04.001)
46. Weisel JW. 2005 Fibrinogen and fibrin. Adv. Protein Chem. 70, 247-299. (doi:10.1016/S0065- 3233(05)70008-5)
47. Watson SW, Novitsky TJ, Quinby HL, Valois FW. 1977 Determination of bacterial number and biomass in the marine environment. Appl. Environ. Microbiol. 33, 940-946.
48. Paiüssé S, Valle C, Servant F, Courtney M, Burcelin R, Amar J, Lelouvier B. 2016 Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion 56, 1138-1147. (doi:10.1111/trf.13477)
49. Ward WH, Holdgate GA. 2001 Isothermal titration calorimetry in drug discovery. Prog. Med. Chem. 38, 309-376. (doi:10.1016/S0079-6468(08)70097-3)
50. Nielsen VG, Kirklin HK, Hoogendoorn H, Ellis TC, Holman WL. 2007 Thromboelastographic method to quantify the contribution of factor XIII to coagulation kinetics. Blood Coagul. Fibrinolysis 18, 145-150. (doi:10.1097/MBC.0b013e32802f7d91)
51. Nielsen VG. 2008 Beyond cell based models of coagulation: analyses of coagulation with clot 'lifespan' resistance-time relationships. Thromb. Res. 122, 145-152. (doi:10.1016/j.thromres.2007. 09.003)
52. Bester J, Soma P, Kell DB, Pretorius E. 2015 Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget Gerontol. 6, 35 284-35 303.
53. Calabrese V, Cighetti R, Peri F. 2015 Molecular simplification of lipid A structure: TLR4-modulating cationic and anionic amphiphiles. Mol. Immunol. 63, 153-161. (doi:10.1016/j.molimm.2014.05.011)
54. Chaby R. 2004 Lipopolysaccharide-binding molecules: transporters, blockers and sensors. Cell. Mol. Life Sci. 61, 1697-1713. (doi:10.1007/s00018- 004-4020-4)
55. Anfinsen CB. 1973 Principles that govern the folding of protein chains. Science 181, 223-230. (doi:10.1126/science.181.4096.223)
56. Carulla N, Zhou M, Arimon M, Gairi M, Giralt E, Robinson CV, Dobson CM. 2009 Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fibril formation. Proc. Natl Acad. Sci. USA 106, 7828-7833. (doi:10.1073/pnas.0812227106)
57. Prusiner SB. 2013 Biology and genetics of prions causing neurodegeneration. Annu. Rev. Genet. 47, 601-623. (doi:10.1146/annurev-genet-110711- 155524)
58. Watts JC et al. 2014 Serial propagation of distinct strains of Abeta prions from Alzheimer's disease patients. Proc. Natl Acad. Sci. USA 111, 10 323-10 328. (doi:10.1073/pnas.1408900111)
59. Kell DB, Pretorius E. In preparation. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. (doi:10.1101/054734)
60. Cohen FE, Prusiner SB. 1998 Pathologic conformations of prion proteins. Annu. Rev. Biochem. 67, 793-819. (doi:10.1146/annurev. biochem.67.1.793)
61. Eisenberg D, Jucker M. 2012 The amyloid state of proteins in human diseases. Cell 148, 1188-1203. (doi:10.1016/j.cell.2012.02.022)
62. Harrison PM, Bamborough P, Daggett V, Prusiner SB, Cohen FE. 1997 The prion folding problem. Curr. Opin Struct. Biol. 7, 53-59. (doi:10.1016/S0959- 440X(97)80007-3)
63. Undas A, Arieüns RAS. 2011 Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 31, e88-e99. (doi:10.1161/ATVBAHA.111.230631)
64. Osterud B, Unruh D, Olsen JO, Kirchhofer D, Owens III AP, Bogdanov VY. 2015 Procoagulant and proinflammatory effects of red blood cells on lipopolysaccharide-stimulated monocytes. J. Thromb. Haemost. 13, 1676-1682. (doi:10.1111/jth.13041)
65. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. 2005 Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25, 9275-9284. (doi:10.1523/JNEUROSCI. 2614-05.2005)
66. Deng X et al. 2014 Lipolysaccharide-induced neuroinflammation is associated with Alzheimer-like amyloidogenic axonal pathology and dendritic degeneration in rats. Adv. Alzheimer Dis. 3, 78-93. (doi:10.4236/aad.2014.32009)
67. Miklossy J. 2008 Chronic inflammation and amyloidogenesis in Alzheimer's disease-role of Spirochetes. J. Alzheimers Dis. 13, 381-391.
68. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. 1999 Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J. Clin. Lab. Anal. 13, 273-279. (doi:10.1002/(SICI)1098-2825(1999)13:6,273::AIDJCLA4.3.0.CO;2-X)
69. Santos NC, Silva AC, Castanho MA, Martins-Silva J, Saldanha C. 2003 Evaluation of lipopolysaccharide aggregation by light scattering spectroscopy. ChemBioChem 4, 96-100. (doi:10.1002/cbic.200390020)
70. Pretorius E, Vermeulen N, Bester J, Lipinski B, Kell DB. 2013 A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy. Toxicol. Mech. Methods 23, 352-359. (doi:10.3109/15376516.2012.762082)
71. Nielsen VG, Pretorius E. 2014 Iron and carbon monoxide enhance coagulation and attenuate fibrinolysis by different mechanisms. Blood Coagul. Fibrinolysis 25, 695-702. (doi:10.1097/MBC.0000000000000128)
72. Nielsen VG, Pretorius E. 2014 Iron-enhanced coagulation is attenuated by chelation A thrombelastographic and ultrastructural analysis. Blood Coagul. Fibrinolysis 25, 845-850. (doi:10.1097/MBC.0000000000000160)